Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03724890 · ClinicalTrials.gov registry record · Phase 1
Study of Avelumab-M3814 Combinations
A Phase 1 study, sponsored by EMD Serono Research & Development Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 57
- Enrollment target
NCT03724890 is a Phase 1 study that has completed, run by EMD Serono Research & Development Institute. The registered enrollment target is 57 participants.
The verdict
NCT03724890, a Phase 1 study, has completed, sponsored by EMD Serono Research & Development Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 57 participants
- Enrollment target
Study Summary
The main purpose of the study was to evaluate a safe, tolerable recommended Phase II dose (RP2D) and/or the maximum tolerated dose (MTD) of M3814 when given in combination with avelumab with and without radiotherapy in participants with selected advanced solid tumors.
Interventions
- RADIATION Radiotherapy
- DRUG Avelumab
- DRUG M3814
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2018-11-27 |
| Est. Completion | 2022-08-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03724890
The ClinicalTrials.gov registry entry for NCT03724890 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EMD Serono Research & Development Institute, which has 81 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Radiotherapy is the first listed.
NCT03724890 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03724890 about?
NCT03724890 is a clinical study titled "Study of Avelumab-M3814 Combinations". The main purpose of the study was to evaluate a safe, tolerable recommended Phase II dose (RP2D) and/or the maximum tolerated dose (MTD) of M3814 when given in combination with avelumab with and without radiotherapy in participants with selected advanced solid tumors.
What is the current status of trial NCT03724890?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 57 participants. The study started on 2018-11-27. Estimated completion is 2022-08-17.
What interventions are being tested in trial NCT03724890?
The interventions under investigation include: Radiotherapy (RADIATION), Avelumab (DRUG), M3814 (DRUG).
Who is sponsoring clinical trial NCT03724890?
This trial is sponsored by EMD Serono Research & Development Institute, which has 81 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.